NASDAQ:PROF Profound Medical Q3 2026 Earnings Date & Estimates $6.92 +0.01 (+0.07%) As of 04:00 PM Eastern This is a fair market value price provided by Massive. Learn more. Profound Medical is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. The conference call is scheduled for 4:30 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 5, 2026TimeAfter Market ClosesConference Call4:30 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Profound Medical in Q3 2026Profound Medical is expected to post earnings of -$0.23 per share on revenue of $6.85 million. In the same quarter a year earlier Profound Medical reported -$0.26 per share on revenue of $5.29 million. Profound Medical last reported on August 6, 2026, posting -$0.26 per share and missing the -$0.22 consensus estimate. Profound Medical has beaten the consensus EPS estimate in 3 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.23Expected Revenue$6.85 millionPrior-Year EPS-$0.26Prior-Year Revenue$5.29 millionExpected Revenue Growth+29.5%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.26 (Missed by -$0.04)Last Quarter Revenue$2.48 millionEPS Beat Rate3 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Profound Medical Q3 2026 Earnings FAQ When does Profound Medical report Q3 2026 earnings? Profound Medical (NASDAQ:PROF) is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. What time is Profound Medical's Q3 2026 earnings call? Profound Medical's Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Profound Medical? Analysts expect Profound Medical to post earnings of -$0.23 per share for Q3 2026. How much revenue is Profound Medical expected to report? The consensus revenue estimate for Profound Medical is $6.85 million for Q3 2026. Profound Medical Earnings HeadlinesProfound Medical, Telix Pharma Sign Co-Education Deal To Advance PSMA-Informed Prostate CareOctober 9 at 9:48 AM | rttnews.comProfound Medical, Telix Pharmaceuticals Enter Prostate-Care Education AgreementOctober 9 at 9:48 AM | finance.yahoo.comThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.October 9 at 1:00 AM | Investors Alley (Ad)Profound Medical and Telix Pharmaceuticals partner to advance prostate cancer imaging and treatment educationOctober 9 at 9:48 AM | msn.comProfound Medical: Q3 Revenue Beats Outlook (Rating Upgrade)October 9 at 8:51 AM | seekingalpha.comProfound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate CareOctober 9 at 8:10 AM | financialpost.comFSee More Profound Medical Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Profound Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Profound Medical and other key companies, straight to your email. Email Address About Profound MedicalProfound Medical (NASDAQ:PROF) Corp. (NASDAQ:PROF) is a medical technology company focused on developing and commercializing incisionless therapies for localized prostate disease. The company’s flagship product is the TULSA-PRO system, which uses real-time magnetic resonance imaging (MRI) guidance and transurethral ultrasound to deliver controlled thermal ablation to targeted prostate tissue. TULSA-PRO is designed to enable physicians to customize treatment based on a patient’s prostate anatomy and disease location. The system is intended to treat prostate tissue while helping preserve surrounding structures, and is used in procedures performed in conjunction with MRI. Profound Medical has also developed related software and procedural technologies to support treatment planning, monitoring and delivery. Founded in Canada, Profound Medical serves hospitals, urology practices and other healthcare providers in North America and selected international markets. The company’s activities include regulatory development, clinical research, commercialization and support of its prostate-focused therapeutic platform. Its products are aimed primarily at physicians treating localized prostate cancer and other prostate conditions.View Profound Medical ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueMicrosoft Is Almost Back to $555—Now the Hard Part BeginsSkydance Just Became a Media Giant—With an $80 Billion Debt Load Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
